Recent Press Releases

US FDA accepts Tresiba® and Ryzodeg® resubmissions for review

Bagsværd, Denmark, 7 April 2015 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has accepted for review the Class II Resubmissions for Tresiba® (insulin...

Top Mid-Cap Biotech Companies Increased Revenues to $26.5 Billion in 2014, says GlobalData

Combined total revenues for peer group of 35 mid-cap biotech companies increased from $24.8 billion in 2013 to $26.5 billion in 2014 Rise was driven by Regeneron and Alexion, both of which posted...

Shire Announces Clear Regulatory Path Forward for SHP465, an Investigational Treatment for Adults with ADHD

Potential Launch of SHP465 Anticipated in Second Half of 2017 Exclusivity for Shire's Overall ADHD Product Portfolio Extends to 2029 Lexington, Mass., USA – April 7, 2015 – Shire...

Shire Comments on USPTO Petitions Related to LIALDA and GATTEX

Shire Comments on USPTO Petitions Related to LIALDA and GATTEX Lexington, Mass. – April 6, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) acknowledges the two petitions filed with the U.S....

Juno Therapeutics Announces Patent Litigation Settlement

Juno Therapeutics Announces Patent Litigation Settlement SEATTLE, April 6, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it entered into a settlement agreement...

WeissLaw LLP: The Auspex Pharmaceuticals, Inc. Acquisition by Teva Pharmaceutical Industries Is the Subject of a Legal Investigation

NEW YORK, April 3, 2015 /PRNewswire/ -- The fairness of the proposed acquisition of Auspex Pharmaceutica

First-of-its-Kind Diabetes Technology Revolutionizes How Glucose Data is Collected and Analyzed for People in India

- ABBOTT RECEIVES APPROVAL IN INDIA FOR FREESTYLE® LIBRE PRO FLASH GLUCOSE MONITORING SYSTEM

ABBOTT PARK, Ill., April 2, 2015 /PRNews

Ariosa's Harmony™ Prenatal Test shown to be superior to conventional pregnancy screening for Down syndrome (Trisomy 21) in largest clinical trial

New England Journal of Medicine publishes findings of largest non-invasive prenatal testing (NIPT) study involving more than 18,500 expectant mothers

Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival Compared With Bicalutamide In Strive Trial

TOKYO and SAN FRANCISCO, April 2, 2015 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ:MDVN) today announced topline results from the Phase 2 STRIVE trial comparing...

UCB to focus on core business in India

UCB to focus on core business in India • UCB to sell its established brands portfolio in India to Dr. Reddy's for € 118 million • UCB to concentrate on its neurology presence...

Catamaran and OptumRx to Combine

Clients and individuals will benefit from enhanced services and cost trend management; combined organization expects to fulfill more than one billion scripts Combining OptumRx's unique medical...

Teva Expands Hypertension Line with Launch of Generic Exforge® Tablets in the United States

JERUSALEM--(BUSINESS WIRE)--Mar. 31, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the launch of the generic equivalent to Exforge® (amlodipine and valsartan) Tablets in four...

Mylan N.V. Announces Commencement of Secondary Public Offering of a Portion of Abbott's Ordinary Shares

Mylan N.V. Announces Commencement of Secondary Public Offering of a Portion of Abbott's Ordinary Shares POTTERS BAR, England, March 30, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today...

Mylan N.V. Announces Commencement of Secondary Public Offering of a Portion of Abbott's Ordinary Shares

POTTERS BAR, England, March 30, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the underwritten public offering (the "Offering") of 35,000,000 ordinary shares held by certain...

Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload

Jadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation Jadenu, taken with or without food, simplifies daily treatment administration...

FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma

Application Designed to Support Conversion of Accelerated to Full FDA Approval

THOUSAND OAKS, Calif., March

AUSPEX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

WILMINGTON, Del., March 30, 2015 /PRNewswire/ -- Rigrodsky & Long, P.A.:

Lilly Announces Date for Diabetes Investor Meeting

INDIANAPOLIS, March 30, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a meeting on

Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference

THOUSAND OAKS, Calif., March 30, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Goldman S